Lv7
4680 积分 2021-07-21 加入
Mezigdomide for multiple myeloma: a focus on phase 2 trial data
11小时前
已完结
SOHO State of the Art Updates and Next Questions | Manuscript Title: Bispecific T-Cell Engagers: Sequencing, B-Cell Maturation Antigen, GPRC5D, and Resistance
11小时前
已完结
Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference
11小时前
已完结
MRD in multiple myeloma: Moving from “minimal” to “measurable”
11小时前
已完结
Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma
1个月前
已完结
Moving beyond R-CHOP in large B-cell lymphoma
1个月前
已关闭
Complement biomarkers during iptacopan treatment
3个月前
已关闭
Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial
4个月前
已关闭
Recent Advances in Extended Half-Life Products, Nonfactor Replacement Therapies, and Gene Therpy for the Treatment of Hemophilia
4个月前
已完结
Expanding the Toolbox With Non‐Factor Therapies
4个月前
已关闭
皖公网安备34019202002308
